CCS
CADX

Crosspoint Capital Strategies’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Crosspoint Capital Strategies’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-782
Closed -$11K – 690
2013
Q4 		$11K Buy
+782
New +$5.65K ﹤0.01% 426

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Crosspoint Capital Strategies's CADX Position: Q1 2014 in Review

Crosspoint Capital Strategies sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 782 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $11K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Crosspoint Capital Strategies reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 782 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $11K.
  • Crosspoint Capital Strategies first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
  • Crosspoint Capital Strategies's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $11K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2014, filed 23 Apr 2014.